BTG plc (LON:BTG)‘s stock had its “buy” rating restated by analysts at Numis Securities Ltd in a research note issued to investors on Wednesday. They currently have a GBX 900 ($12.13) price objective on the stock. Numis Securities Ltd’s target price would suggest a potential upside of 34.93% from the company’s previous close.
A number of other equities analysts have also recently weighed in on BTG. J P Morgan Chase & Co reissued a “neutral” rating and set a GBX 750 ($10.11) price target on shares of BTG plc in a research report on Tuesday, May 23rd. Shore Capital reissued a “not rated” rating on shares of BTG plc in a research report on Thursday, July 13th. Finally, Stifel Nicolaus reissued a “buy” rating and set a GBX 800 ($10.79) price target on shares of BTG plc in a research report on Wednesday, August 30th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of GBX 774.78 ($10.45).
Shares of BTG plc (BTG) opened at 660.50 on Wednesday. BTG plc has a 52 week low of GBX 528.36 and a 52 week high of GBX 738.50. The firm’s 50-day moving average is GBX 672.19 and its 200 day moving average is GBX 655.00. The firm’s market capitalization is GBX 2.54 billion.
WARNING: “BTG plc (BTG) Stock Rating Reaffirmed by Numis Securities Ltd” was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://transcriptdaily.com/2017/09/20/btg-plc-btg-stock-rating-reaffirmed-by-numis-securities-ltd.html.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.